PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31443089-9	2019	The effect of treatment with liposomal suspensions of 5-ASA and CGA was evaluated macroscopically and by measuring myeloperoxidase (MPO) activity.	Mesalamine	54-59	myeloperoxidase	Mus musculus	115-130	
33138176-8	2020	Intrarectal treatment of colitis with 30 mg/kg chitosan alone and with 30 mg/kg 5-ASA for 3 days led to a significant decrease in MPO, ALP, TNF-alpha, IL-6, IL-1beta and NF-kappaB in colitis mice compared to untreated mice.	Mesalamine	80-85	myeloperoxidase	Mus musculus	130-133	
31443089-9	2019	The effect of treatment with liposomal suspensions of 5-ASA and CGA was evaluated macroscopically and by measuring myeloperoxidase (MPO) activity.	Mesalamine	54-59	myeloperoxidase	Mus musculus	132-135	
29407223-8	2018	Therefore, these data demonstrated that an HSA NP formulation has the potential to specifically deliver 5-ASA to an inflamed site where MPO is highly expressed.	Mesalamine	104-109	myeloperoxidase	Mus musculus	136-139	
29407223-1	2018	To develop a new strategy for inflamed site-specific drug delivery in the colon for the treatment of ulcerative colitis (UC), we leveraged on the interaction between myeloperoxidase (MPO) and human serum albumin (HSA) and prepared nanoparticles (HSA NPs) conjugated with 5-aminosalicylic acid (5-ASA).	Mesalamine	271-292	myeloperoxidase	Mus musculus	166-181	
29407223-1	2018	To develop a new strategy for inflamed site-specific drug delivery in the colon for the treatment of ulcerative colitis (UC), we leveraged on the interaction between myeloperoxidase (MPO) and human serum albumin (HSA) and prepared nanoparticles (HSA NPs) conjugated with 5-aminosalicylic acid (5-ASA).	Mesalamine	271-292	myeloperoxidase	Mus musculus	183-186	
29407223-1	2018	To develop a new strategy for inflamed site-specific drug delivery in the colon for the treatment of ulcerative colitis (UC), we leveraged on the interaction between myeloperoxidase (MPO) and human serum albumin (HSA) and prepared nanoparticles (HSA NPs) conjugated with 5-aminosalicylic acid (5-ASA).	Mesalamine	294-299	myeloperoxidase	Mus musculus	166-181	
29407223-1	2018	To develop a new strategy for inflamed site-specific drug delivery in the colon for the treatment of ulcerative colitis (UC), we leveraged on the interaction between myeloperoxidase (MPO) and human serum albumin (HSA) and prepared nanoparticles (HSA NPs) conjugated with 5-aminosalicylic acid (5-ASA).	Mesalamine	294-299	myeloperoxidase	Mus musculus	183-186	
29407223-4	2018	The specific interaction between the 5-ASA-HSA NPs and MPO was observed using quartz crystal microbalance analysis in vitro.	Mesalamine	37-42	myeloperoxidase	Mus musculus	55-58	
27416043-10	2016	In the setting of colitis, 5-ASA significantly restored colon length and decreased myeloperoxidase activity in NAT knockout but not in WT mice.	Mesalamine	27-32	myeloperoxidase	Mus musculus	83-98	
28138699-5	2017	The therapeutic effect of 5-ASA-SiO2 NPs was assessed based on their disease activity index (DAI), colon histopathology, myeloperoxidase (MPO) and levels of tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6).	Mesalamine	26-31	myeloperoxidase	Mus musculus	121-136	
25101553-6	2014	Oral administration of 65, 130 and 195 mg/kg 5-ASA significantly reduced the OVA induced total and differential leucocyte count, TNF-alpha, IL-6, IL-13, nitrite, nitrate, MDA, MPO and TPL levels in the lung lavage samples.	Mesalamine	45-50	myeloperoxidase	Mus musculus	176-179	
34059563-4	2021	Intrarectal treatment of moderate and severe colitis with 5-ASA alone or HA alone at a dose of 30 mg/kg led to a significant decrease in clinical activity and histology scores, myeloperoxidase activity (MPO), TNF-alpha, IL-6 and IL-1beta in colitis mice compared to untreated animals.	Mesalamine	58-63	myeloperoxidase	Mus musculus	177-192	
34059563-4	2021	Intrarectal treatment of moderate and severe colitis with 5-ASA alone or HA alone at a dose of 30 mg/kg led to a significant decrease in clinical activity and histology scores, myeloperoxidase activity (MPO), TNF-alpha, IL-6 and IL-1beta in colitis mice compared to untreated animals.	Mesalamine	58-63	myeloperoxidase	Mus musculus	203-206	
34059563-5	2021	The combination of HA (30 mg/kg) and 5-ASA in severe colitis led to a significant improvement of colitis compared to 5-ASA alone (MPO, moderate, 5-ASA: 1,776 +- 315, 5-ASA+HA: 1,157 +- 561; severe, 5-ASA: 5,742 +- 611, 5-ASA+HA: 2,953 +- 2,611 U/g tissue).	Mesalamine	37-42	myeloperoxidase	Mus musculus	130-133